Power of AI is most evident when put to use to solve long-standing problems in the life-sciences industry. From finding new molecules, new gene, RNA and cell therapies, new and more efficient methods of drug synthesis, to accelerating clinical trials, reducing the time and cost of regulatory compliance and enhancing the effectiveness of health care delivery, AI can dramatically transform every activity in the life-sciences industry.
However, applying AI breakthroughs to challenges in life sciences requires approaches distinct from those in consumer space. For instance, instead of relying on techniques which depend on large data sets being available, it is important to use techniques which can leverage knowledge embedded in bio-medical taxonomies and ontologies.
Also, the best approach to AI powered innovation in life sciences involves close collaboration and quick round-tripping between AI practitioners and experts in life sciences. For example, AI powered In Silico methods are best put in use along-side high-throughput In Vitro/In Vivo techniques, to significantly reduce time to discovery of new therapies.
As the value chain of the Pharma/Biotech industry is fragmented, AI should also be leveraged to fluidly stitch together targeted innovative solutions from rapid new molecule design for hard to target diseases to recruiting for clinical trails and generating safety updates.
AI solutions and capability should be shared and explained to end users, especially aspects related to strengths and shortcomings. Given the cross-disciplinary nature of innovation in modern pharma, AI is not a capability to consume in a black box.
Aganitha is committed to a transparent partnership model that brings AI to pharma rather than make pharma force fit its workflow to suite AI platforms.